Search Results - "MILICEVIC, Z"

Experience from Development of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Dulaglutide for Treatment of Type 2 Diabetes Mellitus by Milicevic, Z

“…The dulaglutide development program included innovative approaches to design a molecule with improved safety/efficacy profile versus other agents from this…”
Get full text

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study by Weinstock, R S, Guerci, B, Umpierrez, G, Nauck, M A, Skrivanek, Z, Milicevic, Z

“…Aims To compare the once-weekly glucagon-like peptide-1 (GLP-1) receptor dulaglutide with the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin after…”
Get full text

Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study by Grunberger, G., Chang, A., Garcia Soria, G., Botros, F. T., Bsharat, R., Milicevic, Z.

“…Diabet. Med. 29, 1260–1267 (2012) Aims  Evaluate dose‐dependent effects of once‐weekly dulaglutide, a glucagon‐like peptide‐1 analogue, on glycaemic control in…”
Get full text

Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5) by Skrivanek, Z., Gaydos, B. L., Chien, J. Y., Geiger, M. J., Heathman, M. A., Berry, S., Anderson, J. H., Forst, T., Milicevic, Z., Berry, D.

“…Aims AWARD‐5 was an adaptive, seamless, double‐blind study comparing dulaglutide, a once‐weekly glucagon‐like peptide‐1 (GLP‐1) receptor agonist, with placebo…”
Get full text

Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide by Milicevic, Z., Anglin, G., Harper, K., Konrad, R. J., Skrivanek, Z., Glaesner, W., Karanikas, C. A., Mace, K.

“…Therapeutic administration of peptides may result in anti‐drug antibody (ADA) formation, hypersensitivity adverse events (AEs) and reduced efficacy. As a large…”
Get full text

Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes by Mari, A., Del Prato, S., Ludvik, B., Milicevic, Z., de la Peña, A., Shurzinske, L., Karanikas, C. A., Pechtner, V.

“…This substudy of the AWARD‐3 trial evaluated the effects of the once‐weekly glucagon‐like peptide‐1 receptor agonist, dulaglutide, versus metformin on glucose…”
Get full text

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study by Weinstock, R. S., Guerci, B., Umpierrez, G., Nauck, M. A., Skrivanek, Z., Milicevic, Z.

“…Aims To compare the once‐weekly glucagon‐like peptide‐1 (GLP‐1) receptor dulaglutide with the dipeptidyl peptidase‐4 (DPP‐4) inhibitor sitagliptin after 104…”
Get full text

А critical role for molecular chaperones in Alzheimer's disease by Milicevic, Z, Spremo-Potparevic, B, Zivkovic, L, Bajic, V

Get full text

Molecular characterization of hsp90 isoforms in colorectal cancer cells and its association with tumour progression by MILICEVIC, Z, BOGOJEVIC, D, MIHAILOVIC, M, PETROVIC, M, KRIVOKAPIC, Z

“…A key role of hsp90 in the activity of various oncogenic proteins and pathways is currently of intense interest. To clarify the molecular basis of biological…”
Get full text

P314 Évaluation des principaux résultats du dulaglutide en administration hebdomadaire comparé à l’insuline glargine, tous deux associés à l’insuline prandiale lispro, selon le taux initial d’HbA1c chez les patients diabétiques de type 2 (DT2) inclus dans l’esssai AWARD-4 (Assessment of weekly administration of dulaglutide in diabetes 4) by Adetunji, O, Jung, H, Jia, N, Milicevic, Z

“…Objectif Analyse post-hoc en sous-groupes de taux initial d’HbA1c, évaluant l’efficacité et la sécurité du dulaglutide en administration hebdomadaire et de…”
Get full text

1.2 - Experience from Development of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Dulaglutide for Treatment of Type 2 Diabetes Mellitus by Milicevic, Z.

Get full text

Effect of two starting insulin regimens in patients with type II diabetes not controlled on a combination of oral antihyperglycemic medications by Milicevic, Z, Hancu, N, Car, N, Ivanyi, T, Schwarzenhofer, M, Jermendy, G

“…In an open-label, 24-week, parallel-group study, 135 patients inadequately controlled with oral antihyperglycemic medications (OAMs) were treated with…”
Get more information

Performance of aquatic weed - Waste Myriophyllum spicatum immobilized in alginate beads for the removal of Pb(II) by Milojković, Jelena V., Lopičić, Zorica R., Anastopoulos, Ioannis P., Petrović, Jelena T., Milićević, Sonja Z., Petrović, Marija S., Stojanović, Mirjana D.

“…A new biosorbent – alginate encapsulated with Myriophyllum spicatum – MsA was investigated for lead ions removal. This biosorbent was characterized by scanning…”
Get full text

A comparison of insulin lispro Mix25™ and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan by Mattoo, V., Milicevic, Z., Malone, J.K., Schwarzenhofer, M., Ekangaki, A., Levitt, L.K., Liong, L.H.C., Rais, N., Tounsi, H.

“…Objective: To compare insulin lispro Mix25 and human insulin 30/70 with regard to their effect on morning and evening postprandial glucose (PPG) control, and…”
Get full text

Mechanism of stearic acid adsorption to calcite by Mihajlović, Slavica R., Vučinić, Dušica R., Sekulić, Živko T., Milićević, Sonja Z., Kolonja, Božo M.

“…This paper presents the interpretation of binding mechanism of stearic acid for calcite surface in two modification methods. In the “dry” method, a surface…”
Get full text

Expression of heat shock protein 70 (HSP70) in patients with colorectal adenocarcinoma--immunohistochemistry and Western blot analysis by Milićević, Z T, Petković, M Z, Drndarević, N C, Pavlović, M D, Todorović, V N

“…The role of heat shock protein 70 (HSP70) expression has been investigated in various types of tumors. There are only little and controversial data about its…”
Get more information

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial by Frias, Juan Pablo, Nauck, Michael A, Van, Joanna, Kutner, Mark E, Cui, Xuewei, Benson, Charles, Urva, Shweta, Gimeno, Ruth E, Milicevic, Zvonko, Robins, Deborah, Haupt, Axel

“…LY3298176 is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for…”
Get full text

Interventions in diabetic patients after myocardial infarction by Milicevic, Z, Raz, I

“…Occurrence of a first acute myocardial infarction (AMI) is associated with further increase in risk of cardiovascular events. This risk is further increase is…”
Get full text

Deregulated sequential motion of centromeres induced by antitumor agents may lead to genome instability in human peripheral blood lymphocytes by Bajic, V, Spremo-Potparevic, B, Milicevic, Z, Zivkovic, L

“…Segregation of chromosomes in anaphase is preceded by a sequential order of centromere separation. Alteration of the sequence of centromere separation or…”
Get more information

Apoptotic versus genotoxic potential of anti-tumor agents: a concept of duality in unity by Vladan, B, Milićević, Z, Biljana, P.-S, Nedeljkovic-Kurepa, A

“…Recent advances in anti-tumor therapy have raised a problem of secondary tumors and tumor resistance. Secondary tumors induced by chemotherapeutic agents as a…”
Get full text